A better option might be to split the business. See if you can sell off the projected future cashflows from sales and plow that cash into drug development. Which leaves the issue of valuing those projected sales, hence Hashan. Just a thought.
PXS Price at posting:
6.1¢ Sentiment: Sell Disclosure: Not Held
